Teriparatide in bisphosphonate-resistant osteoporosis: Microarchitectural changes and clinical results after 6 and 18 months

Calcified Tissue International

Volumn 89, Issue 2, 2011, Pages 130-139

  Jobke, B ^a   Muche, B ^b   Burghardt, A J ^a   Semler, J ^b   Link, T M ^a,c   Majumdar, S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Immanuel Hospital and Rheumaklinik Berlin Buch   (Germany)

^c HELIOS KLINIKUM BERLIN BUCH   (Germany)

Author keywords

CT; Biopsy; Histology; Teriparatide; Tissue mineralization

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; PARATHYROID HORMONE[1-34];

AGED; ARTICLE; BONE BIOPSY; BONE DENSITOMETRY; BONE DENSITY; BONE MASS; BONE MINERALIZATION; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; MICRO-COMPUTED TOMOGRAPHY; MICROMORPHOLOGY; OSSIFICATION; OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ALGORITHMS; BIOPSY; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; TERIPARATIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79960418941     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-011-9500-6     Document Type: Article

References (47)

1. DM Black AV Schwartz KE Ensrud JA Cauley S Levis SA Quandt, et al. 2006 Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial JAMA 296 2927 2938 17190893 10.1001/jama.296.24.2927 1:CAS:528:DC%2BD2sXnvVGh (Pubitemid 46021497)
2. HG Bone D Hosking JP Devogelaer JR Tucci RD Emkey RP Tonino, et al. 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women N Engl J Med 350 1189 1199 15028823 10.1056/NEJMoa030897 1:CAS:528: DC%2BD2cXit12rsLc%3D (Pubitemid 38339363)
3. B Borah TE Dufresne PA Chmielewski TD Johnson A Chines MD Manhart 2004 Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography Bone 34 736 746 15050906 10.1016/j.bone.2003.12.013 1:CAS:528:DC%2BD2cXisF2ntbo%3D (Pubitemid 38393811)
4. EF Eriksen F Melsen E Sod I Barton A Chines 2002 Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis Bone 31 620 625 12477578 10.1016/S8756-3282(02)00869-4 1:CAS:528:DC%2BD38XptlGisrk%3D (Pubitemid 35449706)
5. Jobke B, Kulle B, Semler J, Delling G (2006) Bisphosphonates improve bone microarchitecture in middle-aged males with osteoporosis by reducing bone turnover: a paired biopsy micro-CT analysis over 38 months. J Bone Miner Res 21(Suppl 1)
6. DE Sellmeyer DM Black L Palermo S Greenspan K Ensrud J Bilezikian, et al. 2007 Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis Osteoporos Int 18 973 979 17333451 10.1007/s00198-007-0336-x 1:CAS:528:DC%2BD2sXmt1Sktbs%3D (Pubitemid 46889557)
7. M Arlot PJ Meunier G Boivin L Haddock J Tamayo R Correa-Rotter, et al. 2005 Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters J Bone Miner Res 20 1244 1253 15940379 10.1359/JBMR.050309 1:CAS:528:DC%2BD2MXmsFyitLw%3D (Pubitemid 40863814)
8. Y Jiang JJ Zhao BH Mitlak O Wang HK Genant EF Eriksen 2003 Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure J Bone Miner Res 18 1932 1941 14606504 10.1359/jbmr.2003.18.11.1932 1:CAS:528:DC%2BD3sXptVyiu74%3D (Pubitemid 37377441)
9. MR McClung J San Martin PD Miller R Civitelli F Bandeira M Omizo, et al. 2005 Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass Arch Intern Med 165 1762 1768 16087825 10.1001/archinte. 165.15.1762 1:CAS:528:DC%2BD2MXpslGgs7c%3D (Pubitemid 41138965)
10. P Chen CP Jerome DB Burr CH Turner YL Ma A Rana, et al. 2007 Interrelationships between bone microarchitecture and strength in ovariectomized monkeys treated with teriparatide J Bone Miner Res 22 841 848 17352652 10.1359/jbmr.070310 1:CAS:528:DC%2BD2sXpt12jtr4%3D (Pubitemid 351339744)
11. B Ettinger J San Martin G Crans I Pavo 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate J Bone Miner Res 19 745 751 15068497 10.1359/jbmr.040117 1:CAS:528:DC%2BD2cXktFGksrk%3D (Pubitemid 41094385)
12. P Chen JH Satterwhite AA Licata EM Lewiecki AA Sipos DM Misurski, et al. 2005 Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis J Bone Miner Res 20 962 970 15883636 10.1359/JBMR.050105 1:CAS:528:DC%2BD2MXlsFehtr0%3D (Pubitemid 40712820)
13. H Dobnig 2004 A review of teriparatide and its clinical efficacy in the treatment of osteoporosis Expert Opin Pharmacother 5 1153 1162 15155114 10.1517/14656566.5.5.1153 1:CAS:528:DC%2BD2cXjsVekt7Y%3D (Pubitemid 38702343)
14. H Dobnig A Sipos Y Jiang A Fahrleitner-Pammer LG Ste-Marie JC Gallagher, et al. 2005 Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy J Clin Endocrinol Metab 90 3970 3977 15840739 10.1210/jc.2003-1703 1:CAS:528: DC%2BD2MXmtlCitrg%3D (Pubitemid 41058159)
15. Y Jiang J Zhao EY Liao RC Dai XP Wu HK Genant 2005 Application of micro-CT assessment of 3-D bone microstructure in preclinical and clinical studies J Bone Miner Metab 23 Suppl 122 131 15984427 10.1007/BF03026336
16. B Jobke M Pfeifer HW Minne 2009 Teriparatide following bisphosphonates: initial and long-term effects on microarchitecture and bone remodeling at the human iliac crest Connect Tissue Res 50 46 54 19212852 10.1080/03008200802412462 1:CAS:528:DC%2BD1MXhvVSkt7o%3D
17. BM Obermayer-Pietsch F Marin EV McCloskey P Hadji J Farrerons S Boonen, et al. 2008 Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment J Bone Miner Res 23 1591 1600 18505369 10.1359/jbmr.080506 1:CAS:528:DC%2BD1cXht1OntLfM
18. RJ Moore TC Durbridge AE Woods B Vernon-Roberts 1989 Variation in histomorphometric estimates across different sites of the iliac crest J Clin Pathol 42 814 816 2768521 10.1136/jcp.42.8.814 1:STN:280:DyaL1MzlvF2lsw%3D%3D (Pubitemid 19190750)
19. G Delling T Dreyer M Hahn M Vogel EF Rittinghaus RD Hesch 1990 Morphologic study of iliac crest spongiosa in patients with osteoporosis treated according to the ADFR (activation, depression of resorption, formation, repeat the cycle) with parathyroid hormone and diphosphonates (Hannover PTH I study) [in German] Z Orthop Ihre Grenzgeb 128 1 5 2138378 10.1055/s-2008-1039852 1:STN:280:DyaK3c7psFWmtQ%3D%3D (Pubitemid 20099868)
20. DW Dempster F Cosman ES Kurland H Zhou J Nieves L Woelfert, et al. 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study J Bone Miner Res 16 1846 1853 11585349 10.1359/jbmr.2001.16.10.1846 1:CAS:528: DC%2BD3MXnsVKqtLw%3D (Pubitemid 32911491)
21. BM Misof P Roschger F Cosman ES Kurland W Tesch P Messmer, et al. 2003 Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment J Clin Endocrinol Metab 88 1150 1156 12629098 10.1210/jc.2002-021988 1:CAS:528:DC%2BD3sXit1egu7k%3D (Pubitemid 36337769)
22. EP Paschalis EV Glass DW Donley EF Eriksen 2005 Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial J Clin Endocrinol Metab 90 4644 4649 15914535 10.1210/jc.2004-2489 1:CAS:528:DC%2BD2MXnvVWlurc%3D (Pubitemid 41159354)
23. K Engelke M Karolczak A Lutz U Seibert S Schaller W Kalender 1999 Micro-CT. Technology and application for assessing bone structure Radiologe 39 203 212 10218213 10.1007/s001170050497 1:STN:280:DyaK1M3jsVygtA%3D%3D (Pubitemid 29168702)
24. M Hahn M Vogel M Pompesius-Kempa G Delling 1992 Trabecular bone pattern factor-a new parameter for simple quantification of bone microarchitecture Bone 13 327 330 1389573 10.1016/8756-3282(92)90078-B 1:STN:280:DyaK3s%2FgtFKmtg%3D%3D
25. T Hildebrand P Ruegsegger 1997 Quantification of bone microarchitecture with the structure model index Comput Methods Biomech Biomed Eng 1 15 23 10.1080/01495739708936692
26. R Muller P Ruegsegger 1997 Micro-tomographic imaging for the nondestructive evaluation of trabecular bone architecture Stud Health Technol Inform 40 61 79 10168883 1:STN:280:DyaK2szosVeisQ%3D%3D
27. P Ruegsegger B Koller R Muller 1996 A microtomographic system for the nondestructive evaluation of bone architecture Calcif Tissue Int 58 24 29 8825235 10.1007/BF02509542 1:STN:280:DyaK28vit1Kiug%3D%3D (Pubitemid 26028374)
28. AJ Burghardt GJ Kazakia A Laib S Majumdar 2008 Quantitative assessment of bone tissue mineralization with polychromatic micro-computed tomography Calcif Tissue Int 83 129 138 18685797 10.1007/s00223-008-9158-x 1:CAS:528: DC%2BD1cXhtVyju7fL
29. GJ Kazakia AJ Burghardt S Cheung S Majumdar 2008 Assessment of bone tissue mineralization by conventional X-ray microcomputed tomography: comparison with synchrotron radiation microcomputed tomography and ash measurements Med Phys 35 3170 3179 18697542 10.1118/1.2924210 1:STN:280:DC%2BD1crhsVGmtA%3D%3D (Pubitemid 351904521)
30. F Cosman 2006 Anabolic therapy for osteoporosis: parathyroid hormone Curr Rheumatol Rep 8 63 69 16515768 10.1007/s11926-006-0028-0 1:CAS:528: DC%2BD28XjtFejt7w%3D (Pubitemid 44659363)
31. C Graeff W Timm TN Nickelsen J Farrerons F Marin C Barker, et al. 2007 Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo: results from the EUROFORS study J Bone Miner Res 22 1426 1433 17547537 10.1359/jbmr.070603 1:CAS:528:DC%2BD2sXhtVynsLjI (Pubitemid 351339687)
32. F Jakob F Marin E Martin-Mola D Torgerson P Fardellone S Adami, et al. 2006 Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the observational study of severe osteoporosis (OSSO) QJM 99 531 543 16861718 10.1093/qjmed/hcl073 1:STN:280:DC%2BD28vlslKjtQ%3D%3D (Pubitemid 44304838)
33. EM Lewiecki 2003 Nonresponders to osteoporosis therapy J Clin Densitom 6 307 314 14716042 10.1385/JCD:6:4:307 (Pubitemid 38114506)
34. PD Miller PD Delmas R Lindsay NB Watts M Luckey J Adachi, et al. 2008 Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate J Clin Endocrinol Metab 93 3785 3793 18682511 10.1210/jc.2008-0353 1:CAS:528:DC%2BD1cXht1Gmur%2FN
35. RR Recker SP Bare SY Smith A Varela MA Miller SA Morris, et al. 2009 Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84 Bone 44 113 119 18983947 10.1016/j.bone.2008.09.019 1:CAS:528:DC%2BD1cXhsFahtLjJ
36. P Chen PD Miller R Recker H Resch A Rana I Pavo, et al. 2007 Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis J Bone Miner Res 22 1173 1180 17451369 10.1359/jbmr.070413 1:CAS:528:DC%2BD2sXptlGlsr4%3D (Pubitemid 351339699)
37. Y Chevalier E Quek B Borah G Gross J Stewart T Lang, et al. 2010 Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body Bone 46 41 48 19800436 10.1016/j.bone.2009.09.032 1:CAS:528:DC%2BD1MXhsFynsrvI
38. C Graeff Y Chevalier M Charlebois P Varga D Pahr TN Nickelsen, et al. 2009 Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study J Bone Miner Res 24 1672 1680 19419306 10.1359/jbmr.090416 1:CAS:528: DC%2BD1MXhtlGgurfN
39. BM Misof EP Paschalis R Zoehrer S Blouin N Fratzl-Zelman R Phipps, et al. 2009 Effects of one year daily teriparatide treatment on iliac bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women treated prior with alendronate or risedronate Bone 44 S425 S426 10.1016/j.bone.2009.03.365
40. R Lindsay H Zhou F Cosman J Nieves DW Dempster AB Hodsman 2007 Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium J Bone Miner Res 22 495 502 17227219 10.1359/jbmr.070104 1:CAS:528:DC%2BD2sXpt1Grtrw%3D (Pubitemid 47457425)
41. MC de Vernejoul D Kuntz L Miravet D Goutallier A Ryckewaert 1981 Bone histomorphometric reproducibility in normal patients Calcif Tissue Int 33 369 374 6794875 10.1007/BF02409458 (Pubitemid 12249947)
42. MV Parisien D McMahon N Pushparaj DW Dempster 1988 Trabecular architecture in iliac crest bone biopsies: infra-individual variability in structural parameters and changes with age Bone 9 289 295 3060183 10.1016/8756-3282(88)90012-9 1:STN:280:DyaL1M%2Fns1Kmug%3D%3D (Pubitemid 18262776)
43. NB Watts A Chines WP Olszynski CD McKeever MR McClung X Zhou, et al. 2008 Fracture risk remains reduced one year after discontinuation of risedronate Osteoporos Int 19 365 372 17938986 10.1007/s00198-007-0460-7 1:CAS:528:DC%2BD1cXhtlOqsb4%3D (Pubitemid 351199181)
44. DC Bauer P Garnero MC Hochberg A Santora P Delmas SK Ewing, et al. 2006 Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial J Bone Miner Res 21 292 299 16418785 10.1359/JBMR.051018 1:CAS:528:DC%2BD28Xhs1Kmu7Y%3D (Pubitemid 43265295)
45. RK Fuchs RJ Phipps DB Burr 2008 Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats J Bone Miner Res 23 1689 1697 18466070 10.1359/jbmr.080501 1:CAS:528:DC%2BD1cXht1OntLfE
46. ES Kurland SL Heller B Diamond DJ McMahon F Cosman JP Bilezikian 2004 The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)] Osteoporos Int 15 992 997 15175844 10.1007/s00198-004-1636-z 1:CAS:528:DC%2BD2cXhtVagtr7M (Pubitemid 40064654)
47. DM Black JP Bilezikian KE Ensrud SL Greenspan L Palermo T Hue, et al. 2005 One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis N Engl J Med 353 555 565 16093464 10.1056/NEJMoa050336 1:CAS:528:DC%2BD2MXnsVWmtb0%3D (Pubitemid 41138937)